Hanna Y. Irie
YOU?
Author Swipe
View article: Data from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Data from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Immunotherapies like immune checkpoint inhibitors (ICI) have changed the standard of care for patients with cancer, often leading to durable responses. However, many patients remain or become refractory to ICIs owing to factors such as a l…
View article: Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig7+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig7. Characterizing peripheral cellular immune environment in patients receiving PGV001. Multicolor flowcytometry performed to phenotype circulating immune cells in patients and healthy donors (HD). PID-017 was excluded from…
View article: Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table3 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table3: List of mutated peptide IDs and peptide sequence in each patients’ vaccine
View article: Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig3 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig3. Neoantigen specific antibody responses induced by PGV001. Patient plasma was subjected to seromics by ELISA using linear SLPs in the vaccines. N=12 patients. PID-017 excluded from analysis due to high background. a) Sta…
View article: Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table2 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table2 – Variant count per patient
View article: Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig5+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig5. TCR sequencing on neoantigen reactive T cells in patient PBMCs a) (Top) Depiction of methodology utilized to generate ex vivo and in vitro expanded and stimulated (IVS) T cell samples from screen, week 8 (W8) and week 2…
View article: Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig1+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig1. PGV001 feasibility and recurrence free survival a) Survival plot depicting overall survival (OS). N=12. Median survival depicted by vertical dotted line b) Survival plot depicting recurrence free survival (RFS). Median …
View article: Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table5 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table5: Cellular Immunophenotyping antibody panels
View article: Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table1. from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table1. Staging at time of enrollment, adjuvant treatment following curative intent treatment until the end of vaccination and vaccination timing
View article: Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig6+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig6. Gating strategy for phenotyping of immune cells by flow cytomtery. EM: Effector memory, TEMRA: Effector memory Re-expression RA, CM: Central Memory
View article: Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig4+ Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig4. CD4+ and CD8+ T cell activation by PGV001 PBMCs from patients were expanded in vitro in presence of neoantigen peptides (pools of peptides, OLPs+Mins, corresponding to each vaccine SLP) and restimulated with peptide/s f…
View article: Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supplementary Table4 from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Table4: Number of Subjects who had Treatment Emergent Adverse Events by grade, system (13 subjects)
View article: Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting
Supp Fig2 + Legend from PGV001, a Multi-Peptide Personalized Neoantigen Vaccine Platform: Phase I Study in Patients with Solid and Hematologic Malignancies in the Adjuvant Setting Open
Supplementary Fig2. PGV001-induced T cell immunity as measured by ex vivo IFNγ ELISPOT assay PBMC samples were stimulated with neoantigen peptides (pools of peptides: composed of 15mer OLPs+ 9-10mer predicted Mins corresponding to each vac…
View article: Abstract PO3-27-02: A novel PTK6 PROTAC degrader induces apoptosis of drug resistant breast cancer cells
Abstract PO3-27-02: A novel PTK6 PROTAC degrader induces apoptosis of drug resistant breast cancer cells Open
Background. PTK6/Brk, a non-receptor tyrosine kinase, is an oncogenic driver for several tumor types, including breast, prostate, liver, and pancreatic cancers. PTK6 is expressed in all breast cancer subtypes and higher levels of expressio…
View article: Figure S6 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S6 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Figure S6 shows prognostic significance of MARCH2 levels in different cancer types
View article: Data from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Data from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Epithelial–mesenchymal transition (EMT) in cancer promotes metastasis and chemotherapy resistance. A subset of triple-negative breast cancer (TNBC) exhibits a mesenchymal gene signature that is associated with poor patient outcomes. We pre…
View article: Figure S2 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S2 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Fig S2 shows the effect of PTK6 kinase inhibitor 4f on SNAIL levels in TNBC cells
View article: FIGURE 2 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
FIGURE 2 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
PTK6 inhibition increases ubiquitination and degradation of SNAIL in TNBC. A, PTK6 inhibitor (P21d) treatment or PTK6 shRNA downregulates SNAIL in TNBC cells. Human MDA-MB-231 or mouse MMTV-myc cells were treated with P21d for 24 hours and…
View article: FIGURE 3 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
FIGURE 3 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
MARCH2 is a novel PTK6-regulated SNAIL E3 ligase. A, Schema of siRNA screening strategy used to identify PTK6-regulated SNAIL E3 ligases. B, MARCH2 siRNA (SMART Pool) identified as top candidate siRNA that restores SNAIL expression in P21d…
View article: FIGURE 1 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
FIGURE 1 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Expression of SNAIL and PTK6 in TNBC. A, Prognostic significance of SNAIL expression in TNBC. KM survival curves of SNAIL expression in patients with TNBC (defined as estrogen receptor, progesterone receptor, and HER2 negative) using the M…
View article: Figure S8 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S8 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Figure S8 shows effect of MARCH2 shRNA expression on growth of MDA-MB231 cells
View article: Figure S4 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S4 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Figure S4 shows validation of screening approach and novel SNAIL E3 ligase candidates identifed by screen
View article: FIGURE 6 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
FIGURE 6 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
MARCH2 suppresses growth, migration, survival, and metastases of TNBC. A, MARCH2 expression is associated with favorable prognosis in patients with breast cancer using TCGA data (n = 1,052) and METABRIC data (n = 1302). Breast cancer sampl…
View article: Figure S4 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S4 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Figure S4 shows validation of screening approach and novel SNAIL E3 ligase candidates identifed by screen
View article: FIGURE 3 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
FIGURE 3 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
MARCH2 is a novel PTK6-regulated SNAIL E3 ligase. A, Schema of siRNA screening strategy used to identify PTK6-regulated SNAIL E3 ligases. B, MARCH2 siRNA (SMART Pool) identified as top candidate siRNA that restores SNAIL expression in P21d…
View article: FIGURE 6 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
FIGURE 6 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
MARCH2 suppresses growth, migration, survival, and metastases of TNBC. A, MARCH2 expression is associated with favorable prognosis in patients with breast cancer using TCGA data (n = 1,052) and METABRIC data (n = 1302). Breast cancer sampl…
View article: Figure S7 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S7 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Figure S7 shows effect of MARCH2 overexpression on primary tumor growth of MDA-MB231 LM2-4 primary xenografts
View article: Figure S5 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S5 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Figure S5 shows effect of MARCH2 on levels of EMT driver proteins
View article: Figure S6 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S6 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Figure S6 shows prognostic significance of MARCH2 levels in different cancer types
View article: Figure S1 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases
Figure S1 from MARCH2, a Novel Oncogene-regulated SNAIL E3 Ligase, Suppresses Triple-negative Breast Cancer Metastases Open
Figure S1 shows Kaplan-Meier curves associated with EMT driver genes